Neuronoff, a leader in neuromodulation therapies, has achieved a major milestone with the successful completion of the first-in-human clinical trial for its flagship product, the Injectrode. The study evaluated the safety and effectiveness of the Injectrode, a minimally invasive solution for chronic pain management.